Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GALT's Cash-to-Debt is ranked higher than
99% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. NAS:GALT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GALT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: No Debt Max: No Debt
Current: No Debt
0.41
No Debt
Interest Coverage No Debt
NAS:GALT's Interest Coverage is ranked higher than
99% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 127.83 vs. NAS:GALT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:GALT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -28.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -291.30
NAS:GALT's ROE % is ranked lower than
96% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. NAS:GALT: -291.30 )
Ranked among companies with meaningful ROE % only.
NAS:GALT' s ROE % Range Over the Past 10 Years
Min: -1658.88  Med: -153.68 Max: -107.68
Current: -291.3
-1658.88
-107.68
ROA % -148.15
NAS:GALT's ROA % is ranked lower than
96% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. NAS:GALT: -148.15 )
Ranked among companies with meaningful ROA % only.
NAS:GALT' s ROA % Range Over the Past 10 Years
Min: -1309.12  Med: -143.39 Max: -71.42
Current: -148.15
-1309.12
-71.42
3-Year EBITDA Growth Rate 0.80
NAS:GALT's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:GALT: 0.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GALT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -4.6 Max: 11.4
Current: 0.8
0
11.4
3-Year EPS without NRI Growth Rate -16.40
NAS:GALT's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. NAS:GALT: -16.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:GALT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: -5 Max: 36.2
Current: -16.4
-33.7
36.2
GuruFocus has detected 2 Warning Signs with Galectin Therapeutics Inc NAS:GALT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GALT's 30-Y Financials

Financials (Next Earnings Date: 2018-03-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

GALT Guru Trades in

Q1 2017

GALT Guru Trades in Q1 2017

Charles Brandes 28,500 sh (New)
» More
Q2 2017

GALT Guru Trades in Q2 2017

Charles Brandes 28,500 sh (unchged)
» More
Q3 2017

GALT Guru Trades in Q3 2017

Charles Brandes Sold Out
» More
» Details

Insider Trades

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:XKRX:233990, XTER:93M, OSTO:ORX, HKSE:03737, SGX:1H3, LSE:SUMM, XKLS:7148, NAS:DRRX, TPE:4746, XCNQ:DOJA, IST:DEVA, XMCE:RJF, OTCPK:CBIS, TSXV:ZOM, NAS:TLGT, XKRX:131030, HKSE:06896, LSE:STX, NZSE:AFT, XKRX:206650 » details
Traded in other countries:PHPN.Germany,
Headquarter Location:USA
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc is a biotechnology company. The company is focused on discovery and development. It is engaged in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis.

Ratios

vs
industry
vs
history
EV-to-EBIT -8.27
NAS:GALT's EV-to-EBIT is ranked lower than
99.99% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.21 vs. NAS:GALT: -8.27 )
Ranked among companies with meaningful EV-to-EBIT only.
NAS:GALT' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.5  Med: 0 Max: 0
Current: -8.27
-12.5
0
EV-to-EBITDA -8.27
NAS:GALT's EV-to-EBITDA is ranked lower than
99.99% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. NAS:GALT: -8.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
NAS:GALT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.5  Med: 0 Max: 0
Current: -8.27
-12.5
0
Current Ratio 1.62
NAS:GALT's Current Ratio is ranked lower than
68% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. NAS:GALT: 1.62 )
Ranked among companies with meaningful Current Ratio only.
NAS:GALT' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 3.83 Max: 23.21
Current: 1.62
0.2
23.21
Quick Ratio 1.62
NAS:GALT's Quick Ratio is ranked lower than
56% of the 812 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.88 vs. NAS:GALT: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
NAS:GALT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 3.83 Max: 23.21
Current: 1.62
0.2
23.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.50
NAS:GALT's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.00 vs. NAS:GALT: -20.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAS:GALT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -19.9 Max: -10.6
Current: -20.5
-26.1
-10.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 142.67
NAS:GALT's Price-to-Net-Cash is ranked lower than
92% of the 243 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.78 vs. NAS:GALT: 142.67 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NAS:GALT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.69  Med: 12.28 Max: 210
Current: 142.67
2.69
210
Earnings Yield (Greenblatt) % -12.09
NAS:GALT's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 868 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.18 vs. NAS:GALT: -12.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAS:GALT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25770.33  Med: 0 Max: 4520.18
Current: -12.09
-25770.33
4520.18

More Statistics

EPS (TTM) $ -0.58
Beta3.60
Short Percentage of Float3.14%
52-Week Range $1.28 - 6.74
Shares Outstanding (Mil)35.64

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 15 20 35
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.51 -0.56 -0.64 -0.78
EPS without NRI ($) -0.51 -0.56 -0.64 -0.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}